Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on November 25, 2019 in Ovarian Cancer
Epidemiologic studies reveal population-based disparities in ovarian cancer morbidity and mortality rates.
Web Exclusives published on November 25, 2019 in Ovarian Cancer
Genetic, menstrual, and other factors have been associated with increased risk of ovarian cancer.
Web Exclusives published on November 25, 2019 in Ovarian Cancer
Current screening practices for ovarian cancer continue to result in late-stage diagnoses with consequent poor prognoses.
Web Exclusives published on November 25, 2019 in FDA Updates, In the News

On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease.

  • Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
  • Teva Will Resume Production of Vincristine in Response to Shortage
  • FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
  • FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma
Web Exclusives published on November 14, 2019 in Clinical Trials
New research sponsored by the National Cancer Institute showed that patients with Medicaid or with no insurance had significantly worse overall survival in clinical trials compared with commercially insured patients.
Web Exclusives published on November 14, 2019 in Cholangiocarcinoma
Analysis of the tumor-specific mutation profile of a patient with cholangiocarcinoma can be done through the use of circulating tumor DNA sequencing, which may help to target specific mutations and improve the early diagnosis and treatment selection for this rare type of cancer.
Web Exclusives published on November 11, 2019 in FDA Updates, In the News
  • FDA Approves Ziextenzo, Third Biosimilar to Pegfilgrastim for Febrile Neutropenia
  • Trump Will Nominate Dr Hahn as Next FDA Commissioner
  • Researchers Report High Rates of E-Cigarette Use Among Children and Teens
Web Exclusives published on November 7, 2019 in FDA Updates, Ovarian Cancer

On October 23, 2019, the FDA approved the PARP inhibitor niraparib (Zejula; Tesaro) for the treatment of patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer, after ≥3 chemotherapy regimens. HRD is defined by a deleterious or suspected deleterious BRCA mutation, or a genomic instability associated with disease progression >6 months after the tumor’s response to the last platinum-based chemotherapy. On the same day, the FDA also approved the Myriad myChoice CDx test to select patients for niraparib therapy based on the HRD tumor status.

Page 5 of 19
Results 41 - 50 of 187